Clinical characteristics and patient outcome of study cohort
| . | IDH wild-type (n = 161) . | IDH mutant (n = 62) . | P value . | IDH2 R140Q mutant (n = 26) . |
|---|---|---|---|---|
| Median age, y (range) | 46 (18-60) | 46 (18-60) | .89 | 47 (27-59) |
| Male/female ratio | 80/81 (1:1) | 26/36 (1:1.4) | .37 | 13/13 (1:1) |
| Treatment group, n (%) | .23 | |||
| DNR 45 mg/m2 | 83 (52) | 26 (42) | 8 (31) | |
| DNR 90 mg/m2 | 78 (48) | 36 (58) | 18 (69) | |
| Median WBC count at dx (×109/L) | 31.8 (0.6- 212.8) | 34.7 (1.0-191.8) | .62 | 44.0 (1.7-191.8) |
| Median PLT count at dx (×109/L) | 67.2 (3.9- 452) | 101.7 (6.2- 650) | .002 | 94.3 (17-304) |
| Median BM blast % at dx (range) | 61.2 (8- 99) | 71.8 (22-100) | .009 | 72.2 (25-100) |
| Median PB blast % at dx (range) | 44.9 (0- 98) | 48.4 (0-97) | .49 | 55.8 (0-97) |
| Cytogenetic risk group, n (%) | <.0005 | |||
| Favorable | 0 (0) | 1 (2) | 0 (0) | |
| Intermediate | 146 (91) | 40 (65) | 16 (62) | |
| Unfavorable | 1 (1) | 7 (11) | 4 (15) | |
| Indeterminate | 14 (9) | 14 (23) | 6 (23) | |
| Mutations present, n (%) | ||||
| FLT3-ITD | 76 (48) | 12 (20) | <.0005 | 6 (23) |
| FLT3-TKD | 12 (8) | 2 (3) | 2 (8) | |
| NPM1 | 74 (47) | 32 (53) | .45 | 16 (62) |
| TET2 | 11 (7) | 0 (0) | .087 | 0 (0) |
| DNMT3A | 44 (28) | 20 (33) | .022 | 4 (15) |
| CEBPA | 20 (13) | 1 (2) | .023 | 0 (0) |
| Achieved CR, n (%) | 103 (64) | 40 (65) | .824 | 19 (73) |
| Median survival duration (mo) | 18.2 | 45.3 | .022 | Not reached |
| . | IDH wild-type (n = 161) . | IDH mutant (n = 62) . | P value . | IDH2 R140Q mutant (n = 26) . |
|---|---|---|---|---|
| Median age, y (range) | 46 (18-60) | 46 (18-60) | .89 | 47 (27-59) |
| Male/female ratio | 80/81 (1:1) | 26/36 (1:1.4) | .37 | 13/13 (1:1) |
| Treatment group, n (%) | .23 | |||
| DNR 45 mg/m2 | 83 (52) | 26 (42) | 8 (31) | |
| DNR 90 mg/m2 | 78 (48) | 36 (58) | 18 (69) | |
| Median WBC count at dx (×109/L) | 31.8 (0.6- 212.8) | 34.7 (1.0-191.8) | .62 | 44.0 (1.7-191.8) |
| Median PLT count at dx (×109/L) | 67.2 (3.9- 452) | 101.7 (6.2- 650) | .002 | 94.3 (17-304) |
| Median BM blast % at dx (range) | 61.2 (8- 99) | 71.8 (22-100) | .009 | 72.2 (25-100) |
| Median PB blast % at dx (range) | 44.9 (0- 98) | 48.4 (0-97) | .49 | 55.8 (0-97) |
| Cytogenetic risk group, n (%) | <.0005 | |||
| Favorable | 0 (0) | 1 (2) | 0 (0) | |
| Intermediate | 146 (91) | 40 (65) | 16 (62) | |
| Unfavorable | 1 (1) | 7 (11) | 4 (15) | |
| Indeterminate | 14 (9) | 14 (23) | 6 (23) | |
| Mutations present, n (%) | ||||
| FLT3-ITD | 76 (48) | 12 (20) | <.0005 | 6 (23) |
| FLT3-TKD | 12 (8) | 2 (3) | 2 (8) | |
| NPM1 | 74 (47) | 32 (53) | .45 | 16 (62) |
| TET2 | 11 (7) | 0 (0) | .087 | 0 (0) |
| DNMT3A | 44 (28) | 20 (33) | .022 | 4 (15) |
| CEBPA | 20 (13) | 1 (2) | .023 | 0 (0) |
| Achieved CR, n (%) | 103 (64) | 40 (65) | .824 | 19 (73) |
| Median survival duration (mo) | 18.2 | 45.3 | .022 | Not reached |
DNR, daunorubicin; dx, diagnosis; FLT3-ITD, FLT3 internal tandem duplication; FLT3-TKD, FLT3 tyrosine kinase domain; PLT, platelet